Given their important role in breast cancer predisposition, it is timely that genetic testing include the evaluation of mutations in these additional 23 genes, and not only mutations in BRCA1 and BRCA2, which represents the current testing protocol in cancer genetic clinics. This evidence concerns the gene BRCA2 and cancer.